Back to results
US 2008/0306059 A1Published application
Pyrimido [4,5-B] -Oxazines For Use as Dgat Inhibitors
AssigneeAstraZeneca AB
InventorsAlan Martin Birch, Paul David Kemmitt
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I) or salts thereof, wherein A, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.
Claims13
1:
- A compound of formula (I)
- or a salt thereof,
- wherein:
- R1 is selected from hydrogen, methyl and trifluoromethyl;
- R2 is hydrogen, chloro or fluoro;
- Ring A is (7-10C)bicycloalkanediyl or (8-12C)tricycloalkanediyl;
- R3 is selected from carboxy, —SO3H, —S(O)2NHR13, —S(O)2NHC(O)R13, —CH2S(O)2R13, —C(O)NHS(O)2R13, —C(O)NHOH, —C(O)NHCN, —CH(CF3)OH, —C(CF3)2OH, —P(O)(OH)2,
- R13 is (1-6C)alkyl, aryl or heteroaryl;
- R27 is hydrogen or (1-4C)alkyl;
- R4 and R5 are each independently hydrogen or methyl;
- and
- n is 0 or 1.
9 more elements
2:
- The compound as claimed in claim 1 or a salt thereof wherein R3 is carboxy.
3:
- The compound as claimed in claim 1 or a salt thereof wherein R1 and R2 are both hydrogen.
4:
- The compound as claimed in claim 1, or a salt thereof, wherein Ring A is bicyclooctanediyl, bicyclononanediyl or adamantyl.
5:
- The compound as claimed in claim 1, or a salt thereof, wherein Ring A is bicyclooctanediyl.
6:
- The compound as claimed in claim 1 or a salt thereof wherein:
- R1 is hydrogen;
- R2 is hydrogen;
- Ring A is (8-9C)bicycloalkanediyl or adamantyl;
- R3 is carboxy;
- R4 is hydrogen or methyl;
- R5 is hydrogen;
- and
- n is 0 or 1.
6 more elements
7:
- The compound as claimed in claim 1 or a salt thereof which is any one or more of:
- {4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid;
- and/or
- {3-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]-1-adamantyl}acetic acid;
- 3-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]adamantane-1-carboxylic acid;
- 2-{4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}propanoic acid;
- {5-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[3.2.2]non-1-yl}acetic acid;
- and
- 4-[4-(4-amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]octane-1-carboxylic acid.
6 more elements
8:
- (canceled)
9:
- A method for treating diabetes mellitus and/or obesity in a warm-blooded animal comprising administering to an animal in need thereof a therapeutically effective amount of a compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof.
10-13. (canceled)
14:
- A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or a pharmaceutically-acceptable salt thereof, in association with a pharmaceutically-acceptable excipient or carrier.
15:
- A process for preparing a compound according to claim 1 comprising
- a) reacting a compound of formula (II), wherein R3 is an ester group
- with a compound of formula (III) or a salt thereof,
- wherein L is a leaving group and all other variables are as defined in claim 1 unless otherwise stated, and
- optionally:
- i) hydrolysing the ester R3 to the corresponding carboxylic acid;
- and/or
- ii) forming a salt.
5 more elements
16:
- The compound methyl (4-phenylbicyclo[2.2.2]oct-1-yl)acetate.